cetpinhibition.org

Mechanisms

A decade-spanning review narrows thirty cholesterol-lowering drug targets to six for detailed chemical and mechanistic analysis, including CETP inhibitors (Curr Med Chem 2011)

Original title: Hypercholesterolemia: chemical aspect of approach

Curr Med Chem · · 3

Salakhutdinov NF, Rogoza LN, Tolstikov GA

This review provides the first systematic analysis, covering the preceding decade, of chemical structures and specific activities of cholesterol-regulating agents. Of thirty currently known biological targets for treating hyperlipidemia, six were selected for detailed consideration, divided into two mechanistic classes: cholesterol biosynthesis blockers, comprising HMG-CoA reductase and squalene 2,3-oxide-lanosterol cyclase inhibitors, and regulators of cholesterol transformation in the body, comprising PPARalpha and PPARalpha/gamma agonists, inhibitors of intestinal cholesterol absorption, cholesteryl ester transfer protein (CETP) inhibitors, and regulators of low-density-lipoprotein receptor (LDLR) expression.

Read the paper (DOI)PubMed

Original abstract

This review is the first attempt at systematization and analysis of the literature data (covering the last decade) on the chemical structures and specific activities of cholesterol-regulating agents. Six of thirty currently known biological targets for treating hyperlipidemia were selected and considered. All of the chemical structures under study are divided into two classes with different mechanisms of their activity: cholesterol biosynthesis blockers (HMG-CoA reductase and squalene 2,3-oxide-lanosterol cyclase inhibitors) and regulators of cholesterol transformations in the organism (PPARα and PPARα/γ agonists, inhibitors of intestinal absorption of cholesterol, cholesteryl ester transfer protein (CETP) inhibitors, and regulators of low-density-lipoprotein receptor (LDLR) expression).

mechanisms

Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 19 August 2026. Methods.